ライフサイエンスコーパス: Acinetobacter baumannii

1 erobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii).

2 and the full-length acetyltransferase WeeI (Acinetobacter baumannii).

3 istant strains of Pseudomonas aeruginosa and Acinetobacter baumannii.

4 ctivity do not address MDR pathogens such as Acinetobacter baumannii.

5 (ESBL)-producing Enterobacteriaceae and MDR Acinetobacter baumannii.

6 c, rifabutin (RBT), against highly resistant Acinetobacter baumannii.

7 t defense against the opportunistic pathogen Acinetobacter baumannii.

8 acteriaceae and the class D (OXA) enzymes of Acinetobacter baumannii.

9 ncy against the opportunistic human pathogen Acinetobacter baumannii.

10 designed an assay for the emerging pathogen Acinetobacter baumannii.

11 ella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii.

12 ns caused by Gram-negative pathogens such as Acinetobacter baumannii.

13 consensus method for the active screening of Acinetobacter baumannii.

14 ing the pathogens Pseudomonas aeruginosa and Acinetobacter baumannii.

15 ed protein (Bap) in a bloodstream isolate of Acinetobacter baumannii.

16 Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii.

17 n antibiotic with promising activity against Acinetobacter baumannii.

18 d drug resistance of the nosocomial pathogen Acinetobacter baumannii.

19 ylococcus aureus, Klebsiella pneumoniae, and Acinetobacter baumannii.

20 monas maltophilia, Burkholderia cepacia, and Acinetobacter baumannii.

21 d approach was used to characterize LOS from Acinetobacter baumannii 1205 and 5075.

22 lecular Microbiology, structural analysis in Acinetobacter baumannii 17978 revealed that a pentasacch

23 of the isolates from the Iraqi conflict were Acinetobacter baumannii (189 of 216 isolates).

24 ulation with Pseudomonas aeruginosa PAO1 and Acinetobacter baumannii 19606.

25 Twenty-eight infectious episodes due to Acinetobacter baumannii (46.4%), Klebsiella pneumoniae (

26 deaths were hospital-acquired, mainly due to Acinetobacter baumannii (47.1%) and K. pneumoniae (35.3%

27 acquired, mainly due to multidrug-resistant Acinetobacter baumannii (52.2%), Klebsiella pneumoniae (

28 siella pneumoniae [10], carbapenem-resistant Acinetobacter baumannii [8], carbapenem- and quinolone-r

29 Acinetobacter baumannii (A. baumannii) strains are commo

30 of lipids in Escherichia coli (E. coli) and Acinetobacter baumannii (A. baumannii).

31 Acinetobacter baumannii A118 was isolated from a patient

32 Acinetobacter baumannii (Ab) is a nosocomial pathogen wi

33 Rapid detection of Acinetobacter baumannii (AB) is critical for limiting he

34 trate, carnitine by non-heme iron containing Acinetobacter baumannii (Ab) oxygenase CntA/reductase Cn

35 ial pathogens Acinetobacter nosocomialis and Acinetobacter baumannii ("aCif").

36 sted against the class C cephalosporinase of Acinetobacter baumannii [Acinetobacter-derived cephalosp

37 Acinetobacter baumannii, Acinetobacter nosocomialis, and

38 lmonella enterica, Klebsiella pneumoniae and Acinetobacter baumannii against 28 different antibiotics

39 options exist for extensively drug resistant Acinetobacter baumannii, an emerging threat in ICUs worl

40 l monomicrobial necrotizing fasciitis due to Acinetobacter baumannii, an unusual finding that may be

41 Pathogenic Acinetobacter species, including Acinetobacter baumannii and Acinetobacter nosocomialis,

42 We identify Acinetobacter baumannii and Enterococcus faecium co-asso

43 tal structures of two CdiB transporters from Acinetobacter baumannii and Escherichia coli.

44 kynyl-benzimidazoles was synergistic against Acinetobacter baumannii and Escherichia coli.

45 s and virulence with phage susceptibility in Acinetobacter baumannii and investigated draft genomes o

46 Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae are al

47 in combination against Enterococcus faecium, Acinetobacter baumannii and Klebsiella pneumoniae.

48 log reduction in viable count within 4 h for Acinetobacter baumannii and Klebsiella pneumoniae.

49 clinically relevant Gram-negative pathogens, Acinetobacter baumannii and Klebsiella pneumoniae.

50 gues when used alone lacked activity against Acinetobacter baumannii and Klebsiella pneumoniae; howev

51 n associated with extensively drug-resistant Acinetobacter baumannii and multidrug-resistant Klebsiel

52 ilar protocols have been proposed to include Acinetobacter baumannii and Pseudomonas aeruginosa (SNAP

53 ymyxin resistant recent clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa .

54 ority bacteria included carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, and

55 ent combination against clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa.

56 e-scaffolds would be more effective against Acinetobacter baumannii and Staphylococcus aureus biofil

57 and Gram-negative species (Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus).

58 antibacterial leads against 119 targets from Acinetobacter baumannii and Staphylococcus aureus.

59 erial growth after 24h for Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus.

60 tive (Staphylococcus aureus), gram-negative (Acinetobacter baumannii), and fungal (Candida albicans)

61 tive (Staphylococcus aureus), Gram-negative (Acinetobacter baumannii), and fungal (Candida albicans)

62 Klebsiella pneumonia, Enterobacter cloacae, Acinetobacter baumannii, and methicillin-resistant Staph

63 assifies carbapenemases in Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa duri

64 d 100 well-characterized Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa isol

65 Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa isol

66 he majority of isolates of Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa test

67 ococcus spp., members of the orange complex, Acinetobacter baumannii, and Pseudomonas aeruginosa were

68 ematic in hospitals: Pseudomonas aeruginosa, Acinetobacter baumannii, and Staphylococcus aureus.

69 cally troublesome pathogens, the prokaryote, Acinetobacter baumannii, and the eukaryote, Candida albi

70 of VIM-2 and SPM-1 from Escherichia coli and Acinetobacter baumannii, and their confinement to Pseudo

71 Infections caused by the bacterial pathogen Acinetobacter baumannii are a mounting concern for healt

72 essential genes in Acinetobacter lwoffii and Acinetobacter baumannii are active in vitro and in vivo.

73 esistant forms of the Gram-negative pathogen Acinetobacter baumannii are an emerging threat to human

74 s for infections due to carbapenem-resistant Acinetobacter baumannii are extremely limited.

75 Outbreak strains of Acinetobacter baumannii are highly clonal, and cross-inf

76 -negative bacilli Pseudomonas aeruginosa and Acinetobacter baumannii are increasingly acquiring carba

77 Using Acinetobacter baumannii as the model, we then demonstrat

78 yed for the treatment of multidrug-resistant Acinetobacter baumannii, as it can rapidly develop resis

79 ein 33 (Omp33) is an outer membrane porin of Acinetobacter baumannii associated with carbapenem resis

80 plified samples were Prevotella tannerae and Acinetobacter baumannii at frequencies between 89 and 10

81 activity against the Gram-negative pathogen Acinetobacter baumannii ATCC 17961 (MIC = 0.0078 muM).

82 The efficacy of antimicrobial therapy for Acinetobacter baumannii bacteremia has been difficult to

83 Of particular concern are Acinetobacter baumannii bacteria, which recently emerged

84 al targets in 51% of all wound samples, with Acinetobacter baumannii being the most frequently detect

85 ut in vitro screen to identify inhibitors of Acinetobacter baumannii biofilms using a library of natu

86 thogens that express a T2S system(s) include Acinetobacter baumannii, Burkholderia pseudomallei, Chla

87 nonflagellated, and pathogenic coccobacillus Acinetobacter baumannii, but there is considerable varia

88 smic domains from Pseudomonas aeruginosa and Acinetobacter baumannii by BOCILLIN FL, aztreonam, merop

89 Members of the Acinetobacter baumannii-calcoaceticus complex are nosoco

90 the susceptibilities of 107 isolates of the Acinetobacter baumannii-calcoaceticus complex to amikaci

91 standing of aminoglycoside resistance in the Acinetobacter baumannii-calcoaceticus complex.

92 infected or not with Staphylococcus aureus, Acinetobacter baumannii, Candida albicans, or Aspergillu

93 aphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii, carbapenem-resistant Enterobact

94 Acinetobacter baumannii causes a wide range of nosocomia

95 Acinetobacter baumannii causes severe infections in comp

96 Adhesion is an initial and important step in Acinetobacter baumannii causing infections.

97 cteriaceae spp., Pseudomonas aeruginosa, and Acinetobacter baumannii chosen to provide extreme diagno

98 cient killing by GA was also demonstrated in Acinetobacter baumannii clinical isolates and approximat

99 Genotypes of carbapenem-resistant Acinetobacter baumannii collected by the clinical microb

100 e elements form pathogenicity islands in the Acinetobacter baumannii comM gene.

101 Acinetobacter baumannii complex bacteremia has been iden

102 In this study, we prospectively collected Acinetobacter baumannii complex clinical isolates from a

103 nterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex for patient care until t

104 119 Pseudomonas aeruginosa isolates, and 83 Acinetobacter baumannii complex isolates) were tested.

105 s, from whom the Acinetobacter calcoaceticus-Acinetobacter baumannii complex was isolated over a 14-m

106 Both DD methods performed poorly for Acinetobacter baumannii complex.

107 ydroxyphenylacetate (HPA) 3-hydroxylase from Acinetobacter baumannii consists of a reductase componen

108 We found that Acinetobacter baumannii contains a pgaABCD locus that en

109 Multidrug-resistant Acinetobacter baumannii contamination occurred most freq

110 ruginosa (CP-PA) and carbapenemase-producing Acinetobacter baumannii (CP-AB) and perform a multicente

111 anisms of resistance of carbapenem-resistant Acinetobacter baumannii (CRAB) were determined in hospit

112 tam antibiotics against carbapenem-resistant Acinetobacter baumannii (CRAB), a WHO "critical priority

113 rbapenem-resistant Enterobacteriaceae (CRE), Acinetobacter baumannii (CRAB), and Pseudomonas aerugino

114 tive pathogens, such as carbapenem-resistant Acinetobacter baumannii (CRAB).

115 Acinetobacter baumannii cultures were multidrug resistan

116 tasets, as well as Klebsiella pneumoniae and Acinetobacter baumannii datasets, with whole genome sequ

117 ecium, and silver/copper combination against Acinetobacter baumannii demonstrated antimicrobial syner

118 with MenC or another Gram-negative bacteria, Acinetobacter baumannii, did not inhibit augmented PS-sp

119 jor protein species in the outer membrane of Acinetobacter baumannii does not belong to the high-perm

120 factors associated with transmission risk of Acinetobacter baumannii during patient care.

121 The epidemiology of Acinetobacter baumannii emerging in combat casualties is

122 es its properties to those published for the Acinetobacter baumannii enzyme, an example of the altern

123 igm of clinical infectious disease research, Acinetobacter baumannii, Escherichia coli, Klebsiella pn

124 Other targeted pathogens (Acinetobacter baumannii, extended-spectrum beta-lactamas

125 Acinetobacter baumannii frequently causes nosocomial inf

126 s with molecular methods used to distinguish Acinetobacter baumannii from other members of the A. cal

127 We performed WGS on longitudinal isolates of Acinetobacter baumannii from patients undergoing colisti

128 ideal sampling method for identification of Acinetobacter baumannii from the health care environment

129 comparative analysis on currently completed Acinetobacter baumannii genomes revealed extensive and d

130 the in-hospital mortality was higher in the Acinetobacter baumannii group (16% vs. 13%; odds ratio,

131 cute liver failure were more frequent in the Acinetobacter baumannii group compared to the control gr

132 Acinetobacter baumannii has become an important concern

133 Acinetobacter baumannii has emerged as a highly troubles

134 Although Acinetobacter baumannii has emerged as a significant cau

135 Acinetobacter baumannii has emerged as an important and

136 Acinetobacter baumannii has emerged as an important etio

137 Acinetobacter baumannii has emerged as an important noso

138 t emergence of multidrug resistance (MDR) in Acinetobacter baumannii has raised concern in health car

139 Acinetobacter baumannii has rapidly emerged as a major c

140 Acinetobacter baumannii has recently emerged as a highly

141 rk done over the past 5 years has shown that Acinetobacter baumannii has the remarkable capability to

142 multidrug-resistant, opportunistic pathogen, Acinetobacter baumannii, has spread swiftly through hosp

143 MICs of tigecycline to Acinetobacter baumannii have been reported to be elevate

144 and incidence rates of carbapenem-resistant Acinetobacter baumannii (Hungary), extended-spectrum bet

145 gative pathogens, such as colistin-resistant Acinetobacter baumannii in a mouse peritonitis-sepsis mo

146 of both drug-susceptible and drug-resistant Acinetobacter baumannii in a soft-tissue infection model

147 fect of the presence of carbapenem-resistant Acinetobacter baumannii in accordance with surveillance

148 domonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii in the pediatric population.

149 nfectivity of bacterial pathogens, including Acinetobacter baumannii, in animal models, but the mecha

150 re unit length of stay, and complications of Acinetobacter baumannii including multidrug-resistant st

151 observed with a second respiratory pathogen, Acinetobacter baumannii, indicating that the phenomenon

152 hanced sensitivity to lipopolysaccharide- or Acinetobacter baumannii-induced endotoxemia.

153 Acinetobacter baumannii infection has become a major cau

154 e or clinical indifference, the impact of an Acinetobacter baumannii infection on mortality is inconc

155 Acinetobacter baumannii infection was, however, associat

156 intensive care unit patients with confirmed Acinetobacter baumannii infection were defined as cases.

157 In this single-center experience, Acinetobacter baumannii infection, including multidrug-r

158 -deficient mice were protected from systemic Acinetobacter baumannii infection, suggesting that facto

159 between mortality and colistin resistance in Acinetobacter baumannii infections and the interaction w

160 s for treatment of multidrug-resistant (MDR) Acinetobacter baumannii infections are extremely limited

161 Severe Acinetobacter baumannii infections in immunocompetent pa

162 d Clostridioides difficile and pan-resistant Acinetobacter baumannii infections in murine models.

163 ulfonate (CMS) to treat carbapenem-resistant Acinetobacter baumannii infections, colistin resistance

164 Acinetobacter baumannii infects a wide range of anatomic

165 s Diseases (NSRB) against BasE, an AAAE from Acinetobacter baumannii involved in production of the si

166 Acinetobacter baumannii is a bacterial pathogen of incre

167 Acinetobacter baumannii is a bacterial pathogen with inc

168 Acinetobacter baumannii is a common cause of health care

169 Acinetobacter baumannii is a common nosocomial pathogen

170 Acinetobacter baumannii is a feared, drug-resistant path

171 The nosocomial pathogen Acinetobacter baumannii is a frequent cause of hospital-

172 Acinetobacter baumannii is a globally distributed nosoco

173 Acinetobacter baumannii is a Gram-negative bacterium tha

174 Acinetobacter baumannii is a Gram-negative bacterium tha

175 Acinetobacter baumannii is a Gram-negative coccobacillus

176 Acinetobacter baumannii is a Gram-negative opportunistic

177 Acinetobacter baumannii is a Gram-negative opportunistic

178 Acinetobacter baumannii is a leading cause of multidrug-

179 Acinetobacter baumannii is a leading cause of ventilator

180 Antibiotic resistance in Acinetobacter baumannii is a major global health threat.

181 Acinetobacter baumannii is a multidrug-resistant (MDR) n

182 Acinetobacter baumannii is a nosocomial pathogen capable

183 Acinetobacter baumannii is a nosocomial pathogen for whi

184 Acinetobacter baumannii is a nosocomial pathogen with a

185 Acinetobacter baumannii is a pathogen of increasing medi

186 Acinetobacter baumannii is a pathogen of major importanc

187 Acinetobacter baumannii is a prevalent nosocomial pathog

188 Acinetobacter baumannii is a prevalent pathogen that can

189 The multidrug resistant bacterium Acinetobacter baumannii is a significant cause of nosoco

190 Acinetobacter baumannii is a significant cause of opport

191 Acinetobacter baumannii is a significant source of nosoc

192 enem-associated outer membrane protein) from Acinetobacter baumannii is a small OM protein that has b

193 Acinetobacter baumannii is a successful pathogen respons

194 Multidrug-resistant Acinetobacter baumannii is among the most prevalent bact

195 Acinetobacter baumannii is an emerging bacterial pathoge

196 Acinetobacter baumannii is an emerging human pathogen an

197 Acinetobacter baumannii is an emerging nosocomial, oppor

198 Acinetobacter baumannii is an emerging opportunistic pat

199 Acinetobacter baumannii is an emerging opportunistic pat

200 Acinetobacter baumannii is an emerging, nosocomial patho

201 Acinetobacter baumannii is an important human pathogen d

202 Acinetobacter baumannii is an important nosocomial patho

203 Acinetobacter baumannii is an important nosocomial patho

204 Invasive disease due to Acinetobacter baumannii is an increasing problem in heal

205 Acinetobacter baumannii is an opportunistic and frequent

206 Acinetobacter baumannii is an opportunistic bacterial pa

207 Acinetobacter baumannii is an opportunistic human pathog

208 Acinetobacter baumannii is an opportunistic pathogen tha

209 Bacteremia caused by Acinetobacter baumannii is becoming more frequent among

210 Acinetobacter baumannii is challenging the healthcare co

211 Acinetobacter baumannii is emerging as an important noso

212 Acinetobacter baumannii is one of the most antibiotic-re

213 Extremely drug-resistant (XDR) Acinetobacter baumannii is one of the most commonly enco

214 Multidrug-resistant (MDR) Acinetobacter baumannii is one of the most difficult Gra

215 Acinetobacter baumannii is one of the most notorious hos

216 tivity relationship of vitroprocines against Acinetobacter baumannii is proposed.

217 Currently, Acinetobacter baumannii is recognized as one of the majo

218 n antibiotic with promising activity against Acinetobacter baumannii, is mediated by an intrinsically

219 CPNFs), including Pseudomonas aeruginosa and Acinetobacter baumannii, is necessary to prevent their d

220 contains this coumarate catabolism pathway, Acinetobacter baumannii, is resistant to inhibition by t

221 se collection of epidemiologically unrelated Acinetobacter baumannii isolates to compare the robustne

222 Twenty-eight XDR Acinetobacter baumannii isolates were longitudinally rec

223 rbapenems (imipenem and meropenem); 90.8% of Acinetobacter baumannii isolates were susceptible to min

224 Sixteen isolates (4 Acinetobacter baumannii isolates, 6 Pseudomonas aerugino

225 or 99 isolates of Pseudomonas aeruginosa, 26 Acinetobacter baumannii isolates, and 11 Stenotrophomona

226 pplied to detect beta-lactamases in clinical Acinetobacter baumannii isolates.

227 Moraxella catarrhalis, and most recently in Acinetobacter baumannii, it has become increasingly appa

228 lethal infections with clinical isolates of Acinetobacter baumannii, Klebsiella pneumoniae and E. co

229 en overlooked for priority pathogens such as Acinetobacter baumannii, Klebsiella pneumoniae and Pseud

230 ogenic carbapenem-resistant strains, such as Acinetobacter baumannii, Klebsiella pneumoniae, and Esch

231 stant clinical isolates of Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomo

232 important Gram-negative pathogens including Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomo

233 am-negative bacteria, but colistin-resistant Acinetobacter baumannii lacking lipid A were isolated af

234 Extensively drug-resistant (XDR) Acinetobacter baumannii may cause serious infections in

235 coccus aureus (MRSA) and multidrug-resistant Acinetobacter baumannii (MDR-AB) were assessed.

236 ers for identifying carbapenem resistance in Acinetobacter baumannii, methicillin resistance in Staph

237 To successfully establish an infection, Acinetobacter baumannii must overcome the iron starvatio

238 Acinetobacter baumannii (n = 3687 [26%]) and Pseudomonas

239 -resistant Staphylococcus aureus (n=17), and Acinetobacter baumannii (n=15).

240 mophilus influenzae, Pseudomonas aeruginosa, Acinetobacter baumannii, Neisseria meningitidis, Bactero

241 The importance of the Mla system to Acinetobacter baumannii OM integrity and antibiotic sens

242 aphylococcus aureus and antibiotic resistant Acinetobacter baumannii on a single platform.

243 Few antibiotics are effective against Acinetobacter baumannii, one of the most successful path

244 Infections with Acinetobacter baumannii, one of the most troublesome and

245 Found in Acinetobacter baumannii, OXA-24 is a class D carbapenem

246 rane protein A (OmpA) is a porin involved in Acinetobacter baumannii pathogenesis.

247 ment of a zebrafish infection model to study Acinetobacter baumannii pathogenesis.

248 A thorough understanding of Acinetobacter baumannii pathogenicity is the key to iden

249 Thirty-one Acinetobacter baumannii patients were matched to 62 cont

250 6, Pseudomonas aeruginosa, pandrug-resistant Acinetobacter baumannii (PDRAB), Staphylococcus aureus,

251 Acinetobacter baumannii persists in the medical environm

252 Infections by pan-drug resistant Acinetobacter baumannii plague military and civilian hea

253 activation of MDR Pseudomonas aeruginosa and Acinetobacter baumannii (planktonic cells and biofilms)

254 ic effects of resistance to ciprofloxacin in Acinetobacter baumannii populations.

255 Multidrug resistant (MDR) Acinetobacter baumannii poses a growing threat to global

256 Multidrug resistant (MDR) strains of Acinetobacter baumannii present a serious clinical chall

257 Multidrug-resistant Acinetobacter baumannii presents a global medical crisis

258 The human pathogen Acinetobacter baumannii produces a siderophore called ac

259 taphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Ent

260 taphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Ent

261 taphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Ent

262 taphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Ent

263 in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Ste

264 onfermenting gram-negative bacteria, such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Ste

265 panresistant Gram-negative bacilli, such as Acinetobacter baumannii, requires consideration of nonan

266 Klebsiella spp., Pseudomonas aeruginosa, and Acinetobacter baumannii) resistant to cephalosporins or

267 oli, Vibrio cholerae, Bacillus subtilis, and Acinetobacter baumannii, respectively.

268 n of NAD metabolism in the emerging pathogen Acinetobacter baumannii revealed unique features suggest

269 Investigating the opportunistic pathogen Acinetobacter baumannii's response to Zn starvation, we

270 ork, we show that the opportunistic pathogen Acinetobacter baumannii senses and responds to blue ligh

271 Acinetobacter baumannii, Staphylococcus aureus, and Pseu

272 ly, that this activity is maintained against Acinetobacter baumannii, Stenotrophomonas maltophilia, S

273 Pse-containing exopolysaccharide (EPS) from Acinetobacter baumannii strain 54149 (Ab-54149) to form

274 The opportunistic human pathogen Acinetobacter baumannii strain M2 was found to produce d

275 e and rapid spreading of multidrug-resistant Acinetobacter baumannii strains has become a major healt

276 Multidrug-resistant Acinetobacter baumannii strains have increasingly result

277 (3) CFU mL(-1) of Pseudomonas aeruginosa and Acinetobacter baumannii strains that were undetectable u

278 faecalis, 1,356 Enterobacteriaceae, and 227 Acinetobacter baumannii strains were evaluated.

279 Acinetobacter baumannii strains were highly resistant to

280 t strains of some bacterial species, such as Acinetobacter baumannii strains, cannot be reliably iden

281 lls and antimicrobial activity against seven Acinetobacter baumannii strains, resistant to polymyxin

282 Work on this pathway in Acinetobacter baumannii support conflicting models for t

283 ed genes in a multidrug-resistant isolate of Acinetobacter baumannii that are required for growth and

284 A strain of multidrug-resistant Acinetobacter baumannii that caused a 26% mortality rate

285 o MDR isolates of Pseudomonas aeruginosa and Acinetobacter baumannii through in vitro disk diffusion,

286 The ability of Acinetobacter baumannii to adhere to and persist on surf

287 a representative nosocomial human pathogen, Acinetobacter baumannii, to chlorhexidine to identify th

288 We screened Acinetobacter baumannii transposon mutants and identifie

289 Acinetobacter baumannii was the predominant pathogen (37

290 comial pathogens, Pseudomonas aeruginosa and Acinetobacter baumannii, was also detected using this me

291 Using Acinetobacter baumannii, we provide initial insight into

292 es and blaOXA carbapenemases associated with Acinetobacter baumannii were noted.

293 a pneumoniae and platinum and silver against Acinetobacter baumannii were optimal.

294 l intensive care unit stay was prolonged for Acinetobacter baumannii when compared to controls (media

295 Acinetobacter baumannii, which causes serious infections

296 d carbacephalosporinase producing strains of Acinetobacter baumannii, which have been listed by the W

297 ella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii with an even higher affinity (K(

298 erobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii with various beta-lactamase susc

299 la tularensis, Burkholderia pseudomallei and Acinetobacter baumannii, with a view to exploiting RNase

300 Extensively drug-resistant Acinetobacter baumannii (XDR-Ab) has emerged as a major